ESMO Sarcoma and Rare Cancers 2023 | Vemurafenib and cobimetinib in patients with BRAF-mutated melanoma

Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, discusses the findings from his recently published paper assessing the efficacy of vemurafenib and cobimetinib in patients with BRAF-mutated melanoma. Prof. Rutkowski details that vemurafenib therapy alone resulted in an estimated medical overall survival (OS) of 10 months, whereas combinatory treatment demonstrated an OS of more than one year. Median progression free survival (DFS) was also reported to be 8 months in patients who received combinatory treatment. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.